Stock comparison
Dynavax Technologies
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
DVAX
Dynavax Technologies
Market cap
$1.82B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | DVAX | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 38D | 79B | HALO |
| Benjamin Graham | 59D | 83A | HALO |
| Philip Fisher | 56C | 65B | HALO |
| Peter Lynch | 50C | 53D | HALO |
| Joel Greenblatt | 2F | 40D | HALO |
| Charlie Munger | 40D | 80C | HALO |
| Terry Smith | 48D | 84A | HALO |
Side-by-side metrics
| Metric | DVAX | HALO |
|---|---|---|
| Market cap | $1.82B | $8.1B |
| P/E (TTM) | - | 24.0x |
| EV/EBIT | - | 10.2x |
| ROIC (TTM) | 1.19% | 23.65% |
| Gross margin | 83.17% | 81.24% |
| Net margin | -13.13% | 23.13% |
| Revenue CAGR 5y | 56.22% | 33.23% |
| EPS CAGR 5y | - | -1.98% |
| Debt / Equity | 0.5x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
DVAX leads on
- P/E (TTM)-vs 24.0x+157%
- EV/EBIT-vs 10.2x+102%
- Debt / Equity0.5xvs 1.0x+44%
- Revenue CAGR 5y56.22%vs 33.23%+41%
HALO leads on
- Net margin23.13%vs -13.13%+157%
- ROIC (TTM)23.65%vs 1.19%+95%
- Market cap$8.1Bvs $1.82B+78%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.